Pramlintide

This page contains recent news articles, when available, and an overview of Pramlintide but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Takeda, Amylin to Co-Develop Obesity Drugs  -  ‎Nov 1, 2009‎
The agreement includes Amylin's pramlintide/metreleptin and davalintide, which are in Phase II studies in the United States. Takeda will lead development ... ABC News

Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of ...  -  ‎Oct 19, 2009‎
Phase 2 data from the pramlintide/metreleptin combination treatment clinical program will be the subject of a late-breaking oral presentation. ... Reuters

Combination drugs for weight loss  -  ‎Oct 29, 2009‎
...and adiposity signaling, significantly reduced body weight when compared with placebo or compared with therapy with pramlintide or metreleptin alone. ... TheHeart.Org

AMLN, Green Light from FDA to Its BYETTA for Expanded Use  -  ‎Oct 31, 2009‎
AMLN has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) ... TransWorldNews (press release)

Human Genome rallies, GTX craters  -  ‎Nov 2, 2009‎
Amylin currently has two such products in Phase II development, pramlintide/metreleptin and davalintide. Under the deal, Takeda will pay Amylin $75 million ... MarketWatch

Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare ...  -  ‎Nov 5, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) ... Reuters

Amylin Pharmaceuticals, Inc. Q3 2009 Earnings Call Transcript  -  ‎Oct 20, 2009‎
In the third quarter we announced positive top line Phase II data from pramlintide/metreleptin study. This study is continuing and data from the extension ... Seeking Alpha (blog)

REG-Lilly (Eli) & Co: STATEMENT ON FDA'S BYETTA (EXENATIDE) INJECTION UPDATE  -  ‎Nov 2, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) ... Reuters

Amylin Pharmaceuticals Reports Third Quarter Financial Results  -  ‎Oct 20, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) ... Reuters

Week of Nov. 2, 2009: Eli Lilly Opens Biotech Center; Johnson & Johnson ...  -  ‎Nov 5, 2009‎
The agreement includes products to be developed from Amylin's pipeline, including pramlintide/metreleptin and davalintide, which are compounds currently in ... Pharmaceutical Technology Magazine

Amylin Pharmaceuticals Inc. Reports Operating Results (10-Q)  -  ‎Nov 5, 2009‎
...the completion of our Duration-2, Duration-3 and pramlintide/leptin clinical trials, as well as efficiencies driven by our reduced cost structure. ... GuruFocus.com

DotW: Sesame Street  -  ‎Nov 6, 2009‎
1, Takeda announced it was teaming up with Amylin, taking two obesity candidates off the table: pramlintide/metreleptin and davalintide. ... The IN VIVO Blog (blog)

Amylin Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ...  -  ‎Nov 9, 2009‎
The BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection are the two medicines marketed by the company to treat diabetes. ... PR-Inside.com (Pressemitteilung)

日 다케다, 아밀린과 밀월여행  -  ‎Nov 3, 2009‎
...�?�번 계약�?는 아밀린�?� 비만�? 치료제 '프램린타�?�드(pramlintide)' '다발린타�?�드(davalintide)'등과 양사�?� 비만�?치료제 연구�?서 �?성�?�는 화합물�?� 들어 있다. ... 헬스코리아뉴스

Amylin Pharma与武田�?��?签署授�?��??议  -  ‎Nov 2, 2009‎
...�??议包括开�?�Amylin候选�?��?，涵盖pramlintide/metreleptin与davalintide，这些化�?�物目�?进行第二阶段实验，治疗肥胖症。 �?责声明：本文仅代表作者个人观点，与凤凰 ... 凤凰网

武田薬�?工業�?�米国Ａ�?ｙｌｉｎ社�?��?�抗肥満薬�?�開発・販売契約  -  ‎Nov 1, 2009‎
...今回�?�契約�?��?肥満症を対象�?��?�米国�?�臨床第2相試験を実施中�?�Ｐｒ�?�?ｌｉｎｔｉｄｅ�?Ｍｅｔｒｅｌｅ�?ｔｉｎ�?�よ�?�Ｄ�?ｖ�?ｌｉｎｔｉｄｅを�?�むアミリン社�?�開発 ... サーチナニュース

Комбинирана медикаментозна терапи�? е ефективна за от�?лабване 03 ноември 2009  -  ‎Nov 3, 2009‎
В първото проучване е било у�?тановено, че комбинираната пептидна терапи�? �? pramlintide и metreleptin води до значително намал�?ване на теглото в �?равнение �? ... DoctorBG.com

다께다/아밀린, 비만치료제 공�?�개발 합�?�  -  ‎Nov 3, 2009‎
...김윤�? 기�? �?�본 거대 제약사 다께다와 미국 아밀린(Amylin)사는 비만치료 신약 pramlintide/metreleptin �? davalintide 개발 �? �?용화를 위한 10억 달러 규모�?� ... 메디포뉴스

Takeda compra medicamentos à Amylin  -  ‎Nov 3, 2009‎
...a farmacêutica japonesa vai pagar 75 milhões de dólares adiantados por fármacos da californiana Amylin que incluem o pramlintide/metreleptin eo ... RCM Pharma

Takeda beli paten obat obesitas  -  ‎Nov 2, 2009‎
Takeda yang berbasis di Osaka menyatakan akan membayar uang muka senilai US$75 juta untuk pembelian paten obat, yang mencakup Amylin pramlintide/metrelepin ... Bisnis Indonesia

PicksThatMove: www.PicksThatMove.com: "Picks that move" Alerts ...  -  ‎Aug 24, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) Trading Markets (press release)

Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa ...  -  ‎Aug 24, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Large Market Opportunity...  -  ‎Aug 5, 2009‎
Amylin's pramlintide and metreleptin is currently in phase IIb. That gives Arena, with an NDA planned before the end of the year, the first-mover advantage. Seeking Alpha

Amylin Pharmaceuticals to Webcast Second Quarter Results  -  14 Jul 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Amylin obesity treatment trial fails to impress  -  ‎Jul 9, 2009‎
The Phase II, 28-week study randomized 608 overweight or obese patients to either placebo or various doses of pramlintide, the active ingredient in Symlin, Reuters

Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference  -  ‎Jun 17, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Amylin Pharms�?�表肥胖症治疗实验  -  ‎Jul 9, 2009‎
...(AMLN) 12.29 : Amylin Pharms�?�表为期28周的pramlintide/metreleptin剂�?研究结果为正�?�，这�?�?�并疗法比较pramlintide与metreleptin治疗过�?与肥胖病患。凤凰网

"아밀린, 비만치료 복합신약 효과 �?정�?"  -  ‎Jul 9, 2009‎
...심린�?� 성분�?� 프람린타�?�드(pramlintide)로 당뇨병 치료제�?�며 메트�?렙틴�?� 대사를 조절하는 렙틴 호르몬�?� 합성 유사체�?�다. 체질량지수 35미만�?� �?� 심�?한 과체중 데일리팜

Amylin Pharmaceuticals to Webcast First Quarter Results  -  ‎Apr 9, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Amylin Pharmaceuticals Provides Shareholders with Update Regarding ...  -  ‎Apr 2, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Amylin gears for 3-way proxy fight as Carl Icahn names five ...  -  ‎Apr 8, 2009‎
The company also manufactures other diabetes drugs, like Symlin, or pramlintide acetate, injection, as well as obesity-treatment drugs. RTT News

PennyPerformers.com: "Penny Stocks that Perform" picks are: AMLN ...  -  ‎Mar 30, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) Trading Markets (press release)

Creeping Waistline Speeds Path to Grave, Study Says  -  18 Mar 2009
Amylin is working on a drug that combines pramlintide, the active ingredient in its diabetes drug Symlin, with leptin, a hormone tied to hunger. Bloomberg

마법 같�?� 차세대 비만치료제를 찾아서!  -  18 Mar 2009
...여기서는 �?�미 합성 렙틴�?� 메트�?렙틴(metreleptin)과 합성 아밀린�?� 프람린타�?�드(pramlintide)�?� 제조�? 성공, �?�들�?� 결합한 차세대 비만치료제 개발�? 뛰어들었다 서울경제

Amylin Pharmaceuticals to Present at Cowen and Company Annual ...  -  ‎Mar 10, 2009‎
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release)

Insulin and Weight Gain  -  ‎Mar 1, 2009‎
13-16 Combining insulin therapies with agents that have positive or neutral weight effects, such as metformin and pramlintide, also can minimize ADVANCE for Physician Assistants

Prandial Not Superior to Basal Strategies in Diabetic Survivors of ...  -  ‎Mar 4, 2009‎
...acarbose or pramlintide, which are approved with insulin) and whether the study will be repeated with newer drugs that more effectively lower Medscape

�?有糖尿病之急性心肌梗塞存活者而言膳食控制並未優於一些基本策略  -  ‎Mar 7, 2009‎
Ceriello醫師寫�?�，肯定的是，如果使用其他�?後藥物加上胰島素來�?�到目標，是�?�會�?�得�?一樣的�?果(例如acarbose或者pramlintide這些核准併用胰島素的藥物)，使用�?低臺灣新浪網

�?肥�?�开�?�在�?��?�中行进  -  ‎Feb 24, 2009‎
Amylin公�?�的普兰林肽(Pramlintide)是天然存在的胰激素Amylin的类似物，已获准用于糖尿病治疗。现�?�现该化�?�物对肥胖有效。在一项为期52周的Ⅱ期临床试验中，�?�独用中国医药报

Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice ...  -  Jan 26, 2009
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

A taste of dysglycemia  -  Jan 9, 2009
The patient is at risk for hyperglycemia: have her take pramlintide with every glass of wine. The patient will not be affected because she will spit out the Endocrine Today,

Amylin Pharmaceuticals, Inc Q4 2008 Earnings Call Transcript  -  Jan 27, 2009
We previously announced our commitment to pursue a medicine for obesity that is a combination of analogs of human hormones amylin and leptin: Pramlintide, Seeking Alpha,

Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices  -  Jan 30, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Pharmaceuticals to Webcast Year-End Results  -  Jan 21, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities  -  Jan 12, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PR Newswire (press release),

Amylin Pharmaceuticals to Webcast Year-End Results  -  Jan 22, 2009
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PharmaLive.com (press release),

Obesity: Reviving the promise of leptin  -  Jan 17, 2009
Amylin is testing leptin in combination with its diabetes drug, pramlintide. The current study was supported by the Timothy Murphy Fund, Junior Faculty The Virtual Medical Centre,

Lilly Drug Facing FDA Delay  -  Dec 8, 2008
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) Inside INdiana Business (press release),

Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide ...  -  Dec 9, 2008
Amylin has developed and gained approval for two first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PipelineReview.com (press release),

Amylin Pharmaceuticals Announces Strategic Restructuring and ...  -  Nov 10, 2008
The Company remains fully staffed to grow product revenue from BYETTA(R) (exenatide) injection and SYMLIN(R) (pramlintide acetate) injection and bring MarketWatch

Amylin Pharmaceuticals to Present at Lazard Capital Markets ...  -  Nov 13, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) MarketWatch

Solvay Ends Research on Experimental Obesity Drug  -  Nov 18, 2008
Lorcaserin, pramlintide/leptin and other emerging novel therapies will capture 80 percent of the total obesity market in 2016 as doctors’ switch from the Network Médica,

New consensus statement on the medical management of type 2 diabetes  -  Nov 18, 2008
Other agents, including alpha-glucosidase inhibitors, glinides, pramlintide (Symlin, Amylin) and DDP-IV inhibitors, were not included in the algorithm Endocrine Today,

Company and People Notes: Amylin, AP Pharma, Avigen, and ...  -  Nov 13, 2008
The company remains fully staffed to grow product revenue from “Byetta�? (exenatide) injection and “Symlin�? (pramlintide acetate) injection and bring a Pharmaceutical Technology Magazine,

Endocrinology & Metabolism News  -  Nov 5, 2008
...(Diabetes Care [September 2008] 31 (9):1777) Pramlintide treatment, when used over 12 months as an adjunct to lifestyle intervention and at either a Journal of Clinical Endocrinology and Metabolism,

Noteworthy Developments in Biotech  -  Nov 2, 2008
...short of some of the other candidates currently in late-stage trials (~20 to 25 lbs after 24 weeks for Qnexa, Contrave, and pramlintide/metreleptin). Zacks.com,

Arena: No Near-Term Relief  -  Oct 31, 2008
...short of some of the other candidates currently in late-stage trials (~20 to 25 lbs after 24 weeks for Qnexa, Contrave, and pramlintide/metreleptin). Zacks.com,

GAZETA: Pesquisa sobre obesidade pode estar em risco  -  Oct 27, 2008
Nos EUA, a Amylin Pharmaceuticals está testando sua terapia combinada pramlintide para obesidade. A Arena Pharmaceuticals, com sede em San Diego, Gazeta Mercantil,

Amylin Pharmaceuticals to Webcast Third Quarter Results  -  Oct 16, 2008
Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) PharmaLive.com (press release),

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity ...  -  Oct 2, 2008
In addition to Amylin's lead clinical-stage programs in obesity, pramlintide/metreleptin and AC2307, new findings will also be presented on various PharmaLive.com (press release),

Amylin Resurrects Obesity Drug, in New Combination with Diabetes ...  -  Oct 4, 2008
The Amylin approach is to use pramlintide, a genetically modified version of a hormone that’s secreted from the pancreas to slow down stomach emptying. Xconomy,

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity ...  -  Oct 1, 2008
In addition to Amylin's lead clinical-stage programs in obesity, pramlintide/metreleptin and AC2307, new findings will also be presented on various istockAnalyst.com (press release),

[비만치료제]세계 비만치료제 시장 전�?  -  Oct 7, 2008
...�? �?��?�계열로 아밀린(Amylin)�?� ‘프람린티드/렙틴’(pramlintide/leptin) 복합제�?� 주목�?�다. 프람린티드는 췌장분비 신경호르몬�?� 아밀린�?� 합성 유사체로 �?욕·�?��? 디지틀보사,

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on cancernewsnetwork.org lead to other sites. cancernewsnetwork.org does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is CancerNewsNetwork.org responsible for dead or misdirected links.

IF YOU NEED A LINK OR TEXT REMOVED FROM THIS PAGE PLEASE CONTACT cancernewsnetwork (at) live.com.
We will do our best to accommodate your request.